An interventional study of OCT, FFR, CTA and FFRCT in Coronary Stenosis, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-09.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Coronary Stenosis with a site in Japan — 2 open to participants now, 3 under way, none of them phase 3. Coronary Stenosis · Japan.
Among the 14 studies in Coronary Stenosis with a site in Japan, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 10 with no phase, and was the 12th registered.
326 studies on the registry are indexed under Coronary Stenosis; 57 are open to participants now.
Browse Coronary Stenosis studies →2 of the 14 studies in Coronary Stenosis with a site in Japan are open now. Recruiting first, the newest first:
Duk-Woo Park, MD · Sites in Japan, United States, Australia and 11 more countries
Ages 20+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 40 Coronary Stenosis studies recruiting now, 33 (83%) set no upper age limit and 3 (8%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 104 is below the median of 190 across 191 interventional studies indexed under Coronary Stenosis.
Median enrollment 240 across the 11 interventional studies, 536 across the 3 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 9 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 2 studies filed under Coronary Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Coronary Stenosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Coronary Stenosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Significant left main (LM) stenosis is associated with a poor prognosis, therefore, adequate judgement of the prognostic significance of LM stenosis is essential to improve patients' prognosis. Recently, fractional flow reserve (FFR) has become widespread practice and carries a Class Ia recommendation to assess functional significance of intermediate coronary stenosis in patients with stable angina. Intravascular ultrasound (IVUS)-derived minimum lumen area (MLA) represents an accurate measure to determine LM significance as shown in multiple studies, while optical coherence tomography (OCT) ,which is a novel intracoronary imaging method with a greater spatial resolution (15μm vs. 100μm), faster image acquisition and facilitated image interpretation, OCT derived-MLA has never been validated against FFR and accordingly, it is not mentioned in the current guidelines for myocardial revascularization. Coronary computed tomography angiography (CTA) has emerged as a noninvasive alternative of coronary angiography with its excellent negative predictive value, while the positive predictive value of CTA is limited. Computational fluid dynamics is an emerging method that enables prediction of blood flow in coronary arteries and calculation of FFR from computed tomography (FFRCT) noninvasively. Noninvasive and accurate assessment of functional significance would bring a great benefit for patients with LM stenosis, however, there are no data to evaluate the diagnostic accuracy of FFRCT for LM stenosis in comparison with FFR and minimal lumen area derived by OCT.
This study will investigate the optimal OCT-derived MLA cut-off point and the diagnostic performance of FFRCT for intermediate LM stenosis compared with FFR ≤0.8 as a reference standard.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
Diagnostic Test: OCT, FFR, CTA and FFRCT
Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
OCT vs. FFR
- The area under the curve of OCT-derived MLA for FFR≤0.8
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. FFR
-The optimal cut-off point of OCT-derived MLA from receiver-operator characteristics curves for FFR≤0.8
Time frame: Measurement at Procedure/ Baseline Visit
FFRCT vs. FFR
Diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FFRCT≤0.8 for FFR≤0.8
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. FFR, RFR, resting Pd/Pa, FFRCT, QFR
- The area under the curve and the optimal cut-off point of OCT-derived MLA from receiver-operator characteristics curves for FFR≤0.75, RFR≤0.89, resting Pd/Pa≤0.91, and FFRCT≤0.80 and QFR≤0.80
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. FFR, RFR, resting Pd/Pa, FFRCT
- Predictability of MLA, minimal lumen diameter, area stenosis, lesion length, eccentricity index, and plaque characteristics (plaque rupture, fibroatheroma, and calcification) for FFR ≤0.8, FFR≤0.75, RFR≤0.89, resting Pd/Pa≤0.91, and FFRCT≤0.80 and QFR≤0.80
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. FFR, RFR, resting Pd/Pa, FFRCT
- Correlation among OCT-derived MLA, FFR, RFR, resting Pd/Pa, and FFRCT and QFR
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. CTA
- Correlation between luminal diameter stenosis of CTA and OCT-derived MLA
Time frame: Measurement at Procedure/ Baseline Visit
OCT vs. CTA
- Diagnostic accuracy of plaque characteristics with presumed high risk characteristics including napkin ring sign, low attenuation plaque (\<30HU), positive remodelling (remodelling index \>1.1), and spotty calcium (\<3mm) for thin and thick cap fibroatheroma by OCT.
Time frame: Measurement at Procedure/ Baseline Visit
Clinical endpoint at 1 year
Death
Time frame: 12 Month
Clinical endpoint at 1 year
Myocardial infarction
Time frame: 12 Month
Clinical endpoint at 1 year
Target vessel myocardial infarction
Time frame: 12 Month
Clinical endpoint at 1 year
Target lesion revascularization
Time frame: 12 Month
Clinical endpoint at 1 year
Target vessel revascularization
Time frame: 12 Month
Clinical endpoint at 1 year
Any revascularization
Time frame: 12 Month
Clinical endpoint at 1 year
Stent thrombosis
Time frame: 12 Month
Clinical endpoint at 1 year
Stroke and transient ischemic attack
Time frame: 12 Month
Clinical endpoint at 1 year
Acute renal failure
Time frame: 12 Month
Plan to share: No
Started May 2019 (actual). Primary completion is estimated for Dec 2026, 91 months after the start.
Of 47 non-industry interventional studies with no phase under Coronary Stenosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 66. This study's planned 91 months is above that.
Counting every sponsor, half of 71 studies reached it within 26 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →